Efficacy and tolerability of minocycline augmentation therapy in schizophrenia: A systematic review and meta-analysis of randomized controlled trials

Kazuto Oya, Taro Kishi, Nakao Iwata

Research output: Contribution to journalReview article

47 Citations (Scopus)

Abstract

Objective: This study aimed to perform a comprehensive meta-analysis of minocycline augmentation therapy in patients with schizophrenia receiving antipsychotic agents. Methods: Data published up to 2 June 2014 were obtained from the PubMed, PsycINFO, Google Scholar, and Cochrane Library databases. We conducted a systematic review and meta-analysis of patient data from randomized controlled trials (RCTs) comparing minocycline with placebo. Relative risk (RR), standardized mean difference (SMD), and 95% confidence intervals were calculated. Results: We included four RCTs. The total sample included 330 patients. Minocycline was superior to placebo for decreasing Positive and Negative Syndrome Scale (PANSS) total scores (SMD = -0.70), PANSS negative subscale scores (SMD = -0.86), and PANSS general subscale scores (SMD = -0.50) but was not different from placebo for PANSS positive subscale scores (SMD = -0.26) and depressive symptoms (SMD = -0.28). Minocycline was equivalent to placebo for all-cause discontinuation (RR = 1.10), discontinuation due to inefficacy (RR = 0.42), discontinuation due to adverse events (RR = 1.56), and discontinuation due to death (RR = 3.18). Minocycline was superior to placebo for extrapyramidal side-effect scores (SMD = -0.32). Conclusions: Minocycline may improve the psychopathology of schizophrenia, especially the negative symptoms, and seems to be well tolerated.

Original languageEnglish
Pages (from-to)483-491
Number of pages9
JournalHuman Psychopharmacology
Volume29
Issue number5
DOIs
Publication statusPublished - 01-09-2014

Fingerprint

Minocycline
Meta-Analysis
Schizophrenia
Randomized Controlled Trials
Placebos
Therapeutics
Psychopathology
PubMed
Antipsychotic Agents
Libraries
Databases
Confidence Intervals
Depression

All Science Journal Classification (ASJC) codes

  • Neurology
  • Clinical Neurology
  • Psychiatry and Mental health
  • Pharmacology (medical)

Cite this

@article{2a25ddeb79664aef8189d8c400011bb2,
title = "Efficacy and tolerability of minocycline augmentation therapy in schizophrenia: A systematic review and meta-analysis of randomized controlled trials",
abstract = "Objective: This study aimed to perform a comprehensive meta-analysis of minocycline augmentation therapy in patients with schizophrenia receiving antipsychotic agents. Methods: Data published up to 2 June 2014 were obtained from the PubMed, PsycINFO, Google Scholar, and Cochrane Library databases. We conducted a systematic review and meta-analysis of patient data from randomized controlled trials (RCTs) comparing minocycline with placebo. Relative risk (RR), standardized mean difference (SMD), and 95{\%} confidence intervals were calculated. Results: We included four RCTs. The total sample included 330 patients. Minocycline was superior to placebo for decreasing Positive and Negative Syndrome Scale (PANSS) total scores (SMD = -0.70), PANSS negative subscale scores (SMD = -0.86), and PANSS general subscale scores (SMD = -0.50) but was not different from placebo for PANSS positive subscale scores (SMD = -0.26) and depressive symptoms (SMD = -0.28). Minocycline was equivalent to placebo for all-cause discontinuation (RR = 1.10), discontinuation due to inefficacy (RR = 0.42), discontinuation due to adverse events (RR = 1.56), and discontinuation due to death (RR = 3.18). Minocycline was superior to placebo for extrapyramidal side-effect scores (SMD = -0.32). Conclusions: Minocycline may improve the psychopathology of schizophrenia, especially the negative symptoms, and seems to be well tolerated.",
author = "Kazuto Oya and Taro Kishi and Nakao Iwata",
year = "2014",
month = "9",
day = "1",
doi = "10.1002/hup.2426",
language = "English",
volume = "29",
pages = "483--491",
journal = "Human Psychopharmacology",
issn = "0885-6222",
publisher = "John Wiley and Sons Ltd",
number = "5",

}

Efficacy and tolerability of minocycline augmentation therapy in schizophrenia : A systematic review and meta-analysis of randomized controlled trials. / Oya, Kazuto; Kishi, Taro; Iwata, Nakao.

In: Human Psychopharmacology, Vol. 29, No. 5, 01.09.2014, p. 483-491.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Efficacy and tolerability of minocycline augmentation therapy in schizophrenia

T2 - A systematic review and meta-analysis of randomized controlled trials

AU - Oya, Kazuto

AU - Kishi, Taro

AU - Iwata, Nakao

PY - 2014/9/1

Y1 - 2014/9/1

N2 - Objective: This study aimed to perform a comprehensive meta-analysis of minocycline augmentation therapy in patients with schizophrenia receiving antipsychotic agents. Methods: Data published up to 2 June 2014 were obtained from the PubMed, PsycINFO, Google Scholar, and Cochrane Library databases. We conducted a systematic review and meta-analysis of patient data from randomized controlled trials (RCTs) comparing minocycline with placebo. Relative risk (RR), standardized mean difference (SMD), and 95% confidence intervals were calculated. Results: We included four RCTs. The total sample included 330 patients. Minocycline was superior to placebo for decreasing Positive and Negative Syndrome Scale (PANSS) total scores (SMD = -0.70), PANSS negative subscale scores (SMD = -0.86), and PANSS general subscale scores (SMD = -0.50) but was not different from placebo for PANSS positive subscale scores (SMD = -0.26) and depressive symptoms (SMD = -0.28). Minocycline was equivalent to placebo for all-cause discontinuation (RR = 1.10), discontinuation due to inefficacy (RR = 0.42), discontinuation due to adverse events (RR = 1.56), and discontinuation due to death (RR = 3.18). Minocycline was superior to placebo for extrapyramidal side-effect scores (SMD = -0.32). Conclusions: Minocycline may improve the psychopathology of schizophrenia, especially the negative symptoms, and seems to be well tolerated.

AB - Objective: This study aimed to perform a comprehensive meta-analysis of minocycline augmentation therapy in patients with schizophrenia receiving antipsychotic agents. Methods: Data published up to 2 June 2014 were obtained from the PubMed, PsycINFO, Google Scholar, and Cochrane Library databases. We conducted a systematic review and meta-analysis of patient data from randomized controlled trials (RCTs) comparing minocycline with placebo. Relative risk (RR), standardized mean difference (SMD), and 95% confidence intervals were calculated. Results: We included four RCTs. The total sample included 330 patients. Minocycline was superior to placebo for decreasing Positive and Negative Syndrome Scale (PANSS) total scores (SMD = -0.70), PANSS negative subscale scores (SMD = -0.86), and PANSS general subscale scores (SMD = -0.50) but was not different from placebo for PANSS positive subscale scores (SMD = -0.26) and depressive symptoms (SMD = -0.28). Minocycline was equivalent to placebo for all-cause discontinuation (RR = 1.10), discontinuation due to inefficacy (RR = 0.42), discontinuation due to adverse events (RR = 1.56), and discontinuation due to death (RR = 3.18). Minocycline was superior to placebo for extrapyramidal side-effect scores (SMD = -0.32). Conclusions: Minocycline may improve the psychopathology of schizophrenia, especially the negative symptoms, and seems to be well tolerated.

UR - http://www.scopus.com/inward/record.url?scp=84922705265&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922705265&partnerID=8YFLogxK

U2 - 10.1002/hup.2426

DO - 10.1002/hup.2426

M3 - Review article

C2 - 25087702

AN - SCOPUS:84922705265

VL - 29

SP - 483

EP - 491

JO - Human Psychopharmacology

JF - Human Psychopharmacology

SN - 0885-6222

IS - 5

ER -